All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Diagnoses of myeloproliferative neoplasms (MPN) in pregnancy are very rare, occurring in ~3.2 cases per 100,000 pregnancies per year; equivalent to ~24 patients diagnosed with MPN while pregnant over the course of one year.1 Such diagnoses present unique clinical challenges for both the mother and fetus.
Complications associated with the mother include venous and arterial thromboembolism and hemorrhage, while common fetal complications include blood loss, pre-eclampsia, eclampsia, and intrauterine growth retardation.1 Due to the presence of the fetus, standard MPN therapies such as hydroxyurea and ruxolitinib are not suitable for the treatment of pregnant mothers.1 As a result, clinicians currently rely on aspirin, low molecular weight heparin, and pegylated interferon to control any potential complications and maximize the chances of a healthy birth.1
During a 2023 Global MPN Scientific Foundation (GMPNSF) Educational Symposium, Ellis presented findings from a recent systematic review and meta-analysis investigating whether treatment with aspirin, heparin, interferon, or a combination of treatments is associated with live birth rates and reduced adverse maternal outcomes. Below, we summarize the key findings.
Figure 1. Rates of pregnancy loss in each trimester*
*Adapted from Ellis.1
Overall, the analysis showed that the live birth rate increased 8–10-fold with aspirin or IFN treatment compared with observation alone. Placenta complications were lower than previously reported. Maternal thrombosis remained uncommon and was unaffected by aspirin or IFN treatment. These findings indicate that the management of pregnancy in MPN patients should remain multidisciplinary, with increased emphasis on the use of uterine artery flow patterns to detect potential abnormalities.
Further investigation into the mechanisms of placenta-mediated complications, different treatment options, and consideration of women with previous pregnancy loss or placenta complications will be important to improving outcomes for these patients.
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members provided their recommendations for the top...
Comparing responses of pegylated interferon-alfa and hydroxyurea in patients with ET and PV
Essential thrombocytopenia (ET) and polycythemia vera (PV) are myeloproliferative neoplasms (MPN) that commonly present with high-risk thrombotic events or...
Subscribe to get the best content related to MPN delivered to your inbox